Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sorafenib in advanced hepatocellular carcinoma.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Llovet JM, et al. Among authors: bruix j. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. N Engl J Med. 2008. PMID: 18650514 Free article. Clinical Trial.
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells.
Rodrigo MAM, Michalkova H, Jimenez AMJ, Petrlak F, Do T, Sivak L, Haddad Y, Kubickova P, de Los Rios V, Casal JI, Serrano-Macia M, Delgado TC, Boix L, Bruix J, Martinez Chantar ML, Adam V, Heger Z. Rodrigo MAM, et al. Among authors: bruix j. Biomark Res. 2024 Apr 9;12(1):38. doi: 10.1186/s40364-024-00584-y. Biomark Res. 2024. PMID: 38594765 Free PMC article.
Screening for liver cancer: The good, the bad, and the ugly.
García-Criado Á, Bruix J. García-Criado Á, et al. Among authors: bruix j. Hepatology. 2024 Jan 1;79(1):12-14. doi: 10.1097/HEP.0000000000000539. Epub 2023 Jul 21. Hepatology. 2024. PMID: 37505215 No abstract available.
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric Prediction.
Muñoz-Martínez S, Sapena V, García-Criado Á, Darnell A, Forner A, Belmonte E, Sanduzzi-Zamparelli M, Rimola J, Soler A, Llarch N, Iserte G, Mauro E, Ayuso C, Rios J, Bruix J, Vilana R, Reig M. Muñoz-Martínez S, et al. Among authors: bruix j. Cancers (Basel). 2023 Jun 21;15(13):3269. doi: 10.3390/cancers15133269. Cancers (Basel). 2023. PMID: 37444380 Free PMC article.
Breakthroughs in Hepatocellular Carcinoma Therapies.
Singal AG, Kudo M, Bruix J. Singal AG, et al. Among authors: bruix j. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2135-2149. doi: 10.1016/j.cgh.2023.01.039. Epub 2023 Feb 20. Clin Gastroenterol Hepatol. 2023. PMID: 36813012 Review.
Transarterial Chemoembolization with Anthracyclines-Loaded Polyethylene Glycol Drug Eluting Microspheres for the Treatment of Hepatocellular Carcinoma: A Pooled Multicentric Analysis of Survival in 580 Patients.
Veloso Gomes F, de Baère T, Verset G, Coimbra É, Tovar-Felice G, Malagari K, Bruix J. Veloso Gomes F, et al. Among authors: bruix j. Cardiovasc Intervent Radiol. 2023 Apr;46(4):436-446. doi: 10.1007/s00270-023-03362-9. Epub 2023 Feb 10. Cardiovasc Intervent Radiol. 2023. PMID: 36764953 Free PMC article.
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, Eldawy TE, Bruix J, Frassineti GL, Vaccaro GM, Tschaika M, Scheffold C, Koopmans P, Neely J, Piscaglia F. Yau T, et al. Among authors: bruix j. J Clin Oncol. 2023 Mar 20;41(9):1747-1757. doi: 10.1200/JCO.22.00972. Epub 2022 Dec 13. J Clin Oncol. 2023. PMID: 36512738 Free PMC article. Clinical Trial.
378 results